American Journal of Cardiology
Volume 99, Issue 6 , Pages 785-789 , 15 March 2007

Influence of Preoperative Lipid-Lowering Therapy on Postoperative Outcome in Patients Undergoing Coronary Artery Bypass Grafting

  • Brian D. Powell, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationCorresponding author: Tel: 507-284-3545; fax: 507-284-1203.
  • ,
  • Kevin A. Bybee, MD

      Affiliations

    • Mid America Heart Institute, Cardiovascular Consultants; Kansas City, Missouri.
  • ,
  • Uma Valeti, MD

      Affiliations

    • Department of Cardiology, St. Paul Heart Clinic, St. Paul, Minnesota
  • ,
  • Randal J. Thomas, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
  • ,
  • Stephen L. Kopecky, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
  • ,
  • Charles J. Mullany, MB, MS

      Affiliations

    • Division of Cardiothoracic Surgery, Mayo Clinic, Rochester, Minnesota
  • ,
  • R. Scott Wright, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota

Received 9 August 2006 ,Revised 30 October 2006 ,Accepted 30 October 2006.

References 

  1. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman MA, et al Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation. 2000;102:157–165
  2. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96:2137–2143
  3. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis (A 4-year follow-up). JAMA. 1990;264:3013–3017
  4. Campeau L, Knatterud GL, Domanski M, Hunninghake DB, White CW, Geller NL, et al. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Eng J Med. 1997;336:153–162
  5. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation. 2004;110(suppl):II-45–II-49
  6. Dontani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000;86:1128–1130
  7. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg. 1999;15:394–399
  8. Clark L, Ikonomidis J, Crawford F, Crumbley A, Kratz J, Stroud M, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006;131:679–685
  9. Callahan KO, Katsimaglis G, Tepper MR, Ryan J, Mosby C, Ioannidis JP, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. J Am Coll Cardiol. 2005;45:336–342
  10. Chello M, Carassiti M, Agro F, Mastroroberto P, Pugliese G, Colonna D, et al. Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesthes. 2004;18:605–609
  11. O’Driscoll G, Green D, Taylor R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–1131
  12. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 1999;99:3227–3233
  13. Bustos C, Hernandez-Presa M, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057–2064
  14. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol. 1991;31:512–517
  15. Brull DJ, Sanders J, Rumley A, Lowe G, Humphries SE, Montgomery HE. Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol. 2001;88:431–433
  16. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of staatin therapy on C-reactive protein levels (The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study). JAMA. 2001;286:64–70
  17. Ferguson TB, Coombs LP, Peterson ED. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 2002;287:2221–2227
  18. Mangano DT Group MSoPIR. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309–1317
  19. Collins R, Armitage J, Parish S, Sleight P, Peto R, Group HPS. Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  20. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharm. 2003;41:649–656
  21. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J. 2001;15:1454–1456
  22. Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit. 2003;9(suppl):BR155–BR159
  23. Rendig SV, Symons JD, Amsterdam EA. Effects of statins on myocardial and coronary artery response to ischemia-reperfusion. Can J Phys Pharmacol. 2003;81:1064–1071
  24. Arntz H, Wunderlich W, Schnitzer L, Stern R, Fischer F, Agrawal R, et al. Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease (Results from the Lipid-Coronary Artery Disease (L-CAD) Study). Zeitschr Kardiol. 1999;88:582–590
  25. Bybee K, Wright R, Williams B, Murphy J, Holmes D, Kopecky S. Effect of concomitant or very early statin administration on in-hospital mortality and re-infarction rates in patients with acute myocardial infarction. Am J Cardiol. 2001;87:771–774
  26. Schwarzt GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemc events in acute coronary syndrome: the MIRACL study. JAMA. 2001;285:1711–1718
  27. Kayikcioglu M, Can L, Kultursay H, Payzin S, Turkoglu C. Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiol. 2002;57:295–302
  28. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciasco G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA study. Circulation. 2004;110:674–678
  29. Ali I, Buth K. Preoperative statin use and in-hospital outcomes following heart surgery in patients with unstable angina. Eur J Cardiothorac Surg. 2005;27:1051–1056
  30. Bybee K, Powell B, Valeti V, Rosales A, Kopecky S, Mullany C, et al. Pre-operative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation. 2005;112(suppl I):I-286–I-292

 This work was supported by a grant from Merck & Co., Inc., Whitehouse Station, New Jersey.

PII: S0002-9149(06)02367-8

doi: 10.1016/j.amjcard.2006.10.036

American Journal of Cardiology
Volume 99, Issue 6 , Pages 785-789 , 15 March 2007